Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations

Elie Traer, MD, Nathalie Javidi-Sharifi, Jacqueline Martinez, MS, Isabel English, Jennifer Dunlap, MD, Anupriya Agarwal, Tibor J. Kovacsovics, MD, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker, MD

Blood (2016) 128 (22): 1080.

https://doi.org/10.1182/blood.V128.22.1080.1080

Published: 2016

Journal Articles

FGF2-Containing Exosomes Secreted from Bone Marrow Stromal Cells Protect Leukemia Cells from Tyrosine Kinase Inhibitors

Jacqueline Martinez, MS, Nathalie Javidi-Sharifi, Isabel English, Shelton A. Viola, MD, Danielle Jorgens, PhD, Brian J. Druker, MD, Elie Traer, MD PhD

Blood (2015) 126 (23): 2465.

https://doi.org/10.1182/blood.V126.23.2465.2465

Published: 2015

Journal Articles

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

Elie Traer, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel English, Jacqueline Martinez, Jeffrey W. Tyner, Melissa Wong, Brian J. Druker

Blood (2014) 123 (10): 1516–1524.

https://doi.org/10.1182/blood-2013-07-518381

Published: 2014

Includes: Supplemental data

Journal Articles

FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance

Elie Traer, MD, PhD, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer B Dunlap, MD, Isabel English, Jacqueline Martinez, Tibor J. Kovacsovics, MD, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker

Blood (2013) 122 (21): 2541.

https://doi.org/10.1182/blood.V122.21.2541.2541

Published: 2013

Journal Articles

FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib

Elie Traer, MD, PhD, Nathalie Javidi-Sharifi, Anupriya Agarwal, Jennifer B Dunlap, MD, Isabel English, Jacqueline Martinez, Jeffrey W. Tyner, Melissa Wong, PhD, Brian J. Druker

Blood (2013) 122 (21): 3983.

https://doi.org/10.1182/blood.V122.21.3983.3983

Published: 2013

NARROW

FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations

FGF2-Containing Exosomes Secreted from Bone Marrow Stromal Cells Protect Leukemia Cells from Tyrosine Kinase Inhibitors

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance

FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib

Email alerts

ASH Publications

American Society of Hematology

FGF2 from Bone Marrow Stroma Protects Acute Myeloid Leukemia Cells from the FLT3 Inhibitor Quizartinib and Facilitates Acquisition of Resistance Mutations

FGF2-Containing Exosomes Secreted from Bone Marrow Stromal Cells Protect Leukemia Cells from Tyrosine Kinase Inhibitors

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance

FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only